DOP2006000112A - Nuevos derivados de fluoreno, composiciones que los contienen y utilización - Google Patents
Nuevos derivados de fluoreno, composiciones que los contienen y utilizaciónInfo
- Publication number
- DOP2006000112A DOP2006000112A DO2006000112A DO2006000112A DOP2006000112A DO P2006000112 A DOP2006000112 A DO P2006000112A DO 2006000112 A DO2006000112 A DO 2006000112A DO 2006000112 A DO2006000112 A DO 2006000112A DO P2006000112 A DOP2006000112 A DO P2006000112A
- Authority
- DO
- Dominican Republic
- Prior art keywords
- alkyl
- carboxy
- compositions
- contain
- heteroaryl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Neurology (AREA)
- Pulmonology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Obesity (AREA)
- Oncology (AREA)
- Immunology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Psychiatry (AREA)
- Ophthalmology & Optometry (AREA)
- Emergency Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Dermatology (AREA)
- Endocrinology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Compositions Of Macromolecular Compounds (AREA)
Abstract
La invencion se refiere a nuevos productos de la formula (I): en la que Al, A2, A3 y A4 representan CRa o N; R1 y R1' son tales que uno representa H, Hal, alquilo-C1C3, alcoxi-C1C3, alquil-OH, CF3, ciano, carboxi o carboxamido; y el otro representa H; Hal; CF3; OH; SH; nitro; amino; NH-OH; NH-CO-H; NH-CO-OH, NH-CO-Oalquilo, NH-CO-NH2; carboxi; CN; CO-NH2; X-(CH2)m-alquilo; X-(CH2)m-cicloalquilo; X-(CH2)m-heterocicloalquilo; X(CH2)m-arilo o X-(CH2)m-heteroarilo con X = enlace sencillo, CH2, CH=CH, CH2-O, CH2-NH, CH2-C(O), CH2-C(O)-O, CH2-C(O)-NH, CH2-NH-(CO), CH2-NH-S(O), CH2-NH-S(O)2, 0, S, NH, O-C(O), C(O)-NH, -NH-C(O), -NH-C(O)-C(O)-, -NH-C(O)NH-, NH-CS, NH-S(O) o NH-S(O)2; m = 0, 1 0 2; o bien R1 y R'1 forman con los C a los que estan unidos o bien un radical =O; =S; =N-OH; =N-NH2; =N-NH-CO-NH2, =CH-OH; =Yl-(CH2)m-arilo o =Y1-(CH2)m - heteroarilo, en los cuales Y1 representa CH, CH-CO-, CH-CO-NH, N, N-O o N-NH-, con m = 0, 1 0 2, o bien un ciclo, R2 y R'2, representan H, halogeno, CF3, nitro, ciano, alquilo, hidroxi, mercapto, amino, alquilamino, dialquilamino, alcoxi, alquiltio, carboxi libre o esterificado, carboxamida, CO-NH(alquil) y CO N(alquil)2, p= 1 a 3 y p'= 1 a 4; Ra representa H; halogeno; CF3; hidroxi; mercapto; nitro; amino; NH-OH; NH-CO-H; NH-CO-NH2; carboxi; CN; CO-NH2; Y-(CH2)n-alquilo; Y-(CH2)n-cicloalquilo, Y(CH2)n-heterocicloalquilo, Y-(CH2)n-arilo o Y-(CH2)n-heteroarilo, con Y = 0, S, NH, O-C(O), C(O)-NH, NH-C(O), NH-S(O) o NH-S(O)2, con n = 0, 1, 2 0 3,
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR0505037A FR2885904B1 (fr) | 2005-05-19 | 2005-05-19 | Nouveaux derives du fluorene, compositions les contenant et utilisation |
Publications (1)
Publication Number | Publication Date |
---|---|
DOP2006000112A true DOP2006000112A (es) | 2007-01-31 |
Family
ID=36036699
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DO2006000112A DOP2006000112A (es) | 2005-05-19 | 2006-05-12 | Nuevos derivados de fluoreno, composiciones que los contienen y utilización |
Country Status (31)
Country | Link |
---|---|
US (1) | US7674795B2 (es) |
EP (1) | EP1888579B1 (es) |
JP (1) | JP4964874B2 (es) |
KR (1) | KR101288696B1 (es) |
CN (1) | CN101203518B (es) |
AR (1) | AR054125A1 (es) |
AT (1) | ATE518859T1 (es) |
AU (1) | AU2006248825B2 (es) |
BR (1) | BRPI0611424A2 (es) |
CA (1) | CA2608378C (es) |
CR (1) | CR9515A (es) |
DO (1) | DOP2006000112A (es) |
EA (1) | EA019027B1 (es) |
FR (1) | FR2885904B1 (es) |
GT (1) | GT200600206A (es) |
HN (1) | HN2006018410A (es) |
IL (1) | IL187163A (es) |
JO (1) | JO2753B1 (es) |
MA (1) | MA29493B1 (es) |
MX (1) | MX2007014443A (es) |
MY (1) | MY149037A (es) |
NO (1) | NO20076460L (es) |
NZ (1) | NZ563239A (es) |
PA (1) | PA8675701A1 (es) |
PE (1) | PE20061367A1 (es) |
TN (1) | TNSN07389A1 (es) |
TW (1) | TWI386406B (es) |
UA (1) | UA93203C2 (es) |
UY (1) | UY29549A1 (es) |
WO (1) | WO2006123061A2 (es) |
ZA (1) | ZA200709856B (es) |
Families Citing this family (44)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2645551C (en) | 2006-03-16 | 2016-06-28 | Renovis, Inc. | Bicycloheteroaryl compounds as p2x7 modulators and uses thereof |
FR2907453B1 (fr) * | 2006-10-24 | 2008-12-26 | Sanofi Aventis Sa | Nouveaux derives du fluorene,compositions les contenant et utilisation |
KR20100106414A (ko) * | 2007-11-22 | 2010-10-01 | 이데미쓰 고산 가부시키가이샤 | 유기 el 소자 |
CN102046598B (zh) * | 2008-03-31 | 2015-02-04 | 科学与工业研究委员会 | 给体-受体芴支架:其方法和用途 |
GB0809314D0 (en) * | 2008-05-22 | 2008-07-02 | Summit Corp Plc | Compounds for treating muscular dystrophy |
WO2009158118A2 (en) | 2008-05-30 | 2009-12-30 | University Of Notre Dame Du Lac | Anti-bacterial agents from benzo[d]heterocyclic scaffolds for prevention and treatment of multidrug resistant bacteria |
FR2932484B1 (fr) * | 2008-06-16 | 2010-06-18 | Sanofi Aventis | Nouveaux derives de pyrroloindole inhibiteurs d'hsp90, compositions les contenant et utilisation |
CN105012282A (zh) * | 2008-07-02 | 2015-11-04 | 不列颠哥伦比亚癌症局分支机构 | 二缩水甘油醚衍生物治疗剂和它们的使用方法 |
AR074797A1 (es) | 2008-10-10 | 2011-02-16 | Japan Tobacco Inc | Compuesto de fluoreno , composiciones farmaceuticas , inhibidores de pdhk y pdhk2 , metodos de tratamiento , usos de los mismos y kit comercial |
AR077405A1 (es) | 2009-07-10 | 2011-08-24 | Sanofi Aventis | Derivados del indol inhibidores de hsp90, composiciones que los contienen y utilizacion de los mismos para el tratamiento del cancer |
FR2949467B1 (fr) | 2009-09-03 | 2011-11-25 | Sanofi Aventis | Nouveaux derives de 5,6,7,8-tetrahydroindolizine inhibiteurs d'hsp90, compositions les contenant et utilisation |
WO2011082487A1 (en) | 2010-01-06 | 2011-07-14 | British Columbia Cancer Agency Branch | Bisphenol derivatives and their use as androgen receptor activity modulators |
US9290485B2 (en) | 2010-08-04 | 2016-03-22 | Novartis Ag | N-((6-amino-pyridin-3-yl)methyl)-heteroaryl-carboxamides |
WO2012145330A1 (en) * | 2011-04-18 | 2012-10-26 | The University Of British Columbia | Fluorene-9-bisphenol compounds and methods for their use |
CN102442973A (zh) * | 2011-09-22 | 2012-05-09 | 华东理工大学 | 催化氧化伯醇闭环合成苯并咪唑和苯并噻唑化合物的方法 |
CN104093689A (zh) | 2012-01-31 | 2014-10-08 | 剑桥显示技术有限公司 | 聚合物 |
US9365510B2 (en) | 2012-04-16 | 2016-06-14 | British Columbia Cancer Agency Branch | Aziridine bisphenol ethers and related compounds and methods for their use |
AU2013266086B2 (en) | 2012-05-25 | 2018-03-01 | Berg Llc | Methods of treating a metabolic syndrome by modulating heat shock protein (HSP) 90-beta |
SI2975028T1 (en) | 2013-03-15 | 2018-07-31 | Japan Tobacco, Inc. | PIRAZOL-AMIDIC COMPOUNDS AND MEDICINAL USE FORM |
US9173939B2 (en) | 2013-05-10 | 2015-11-03 | The University Of British Columbia | Ester derivatives of androgen receptor modulators and methods for their use |
GB201311888D0 (en) | 2013-07-03 | 2013-08-14 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
GB201311891D0 (en) | 2013-07-03 | 2013-08-14 | Glaxosmithkline Ip Dev Ltd | Novel compound |
WO2015031984A1 (en) | 2013-09-09 | 2015-03-12 | British Columbia Cancer Agency Branch | Halogenated compounds for cancer imaging and treatment and methods for their use |
KR102280686B1 (ko) | 2014-02-11 | 2021-07-22 | 삼성전자주식회사 | 카바졸계 화합물 및 이를 포함한 유기 발광 소자 |
AU2015247817C1 (en) * | 2014-04-14 | 2022-02-10 | Arvinas Operations, Inc. | Imide-based modulators of proteolysis and associated methods of use |
AU2015269054A1 (en) | 2014-06-06 | 2017-01-12 | Berg Llc | Methods of treating a metabolic syndrome by modulating heat shock protein (HSP) 90-beta |
US11426386B2 (en) | 2014-12-05 | 2022-08-30 | Case Western Reserve University | Compositions and methods of modulating S-nitrosylation |
AU2015357489A1 (en) | 2014-12-05 | 2017-07-06 | Case Western Reserve University | Compositions and methods of modulating S-nitrosylation |
DK3245193T3 (da) | 2015-01-13 | 2022-03-07 | British Columbia Cancer Agency Branch | Heterocycliske forbindelser til billedscanning og behandling af cancer samt fremgangsmåder til anvendelse af disse |
US10471023B2 (en) | 2015-03-12 | 2019-11-12 | British Columbia Cancer Agency Branch | Bisphenol ether derivatives and methods for using the same |
CN108136044B (zh) * | 2015-06-04 | 2021-08-10 | 阿尔维纳斯运营股份有限公司 | 基于酰亚胺的蛋白水解调节剂和相关使用方法 |
US20170298033A1 (en) | 2016-04-15 | 2017-10-19 | The University Of British Columbia | Bisphenol derivatives and their use as androgen receptor activity modulators |
MX2019001228A (es) | 2016-07-29 | 2019-06-03 | Japan Tobacco Inc | Metodo de produccion del compuesto de pirazol-amida. |
US11576900B2 (en) | 2017-09-25 | 2023-02-14 | Case Western Reserve University | Compositions and methods of reducing serum cholesterol and PCSK9 |
US11485713B2 (en) | 2018-05-25 | 2022-11-01 | Essa Pharma, Inc. | Androgen receptor modulators and methods for their use |
US11931339B2 (en) | 2018-06-25 | 2024-03-19 | Case Western Reserve University | Compositions and methods for treating tissue injury |
EP3852750A4 (en) * | 2018-09-21 | 2022-05-11 | Case Western Reserve University | ALDOKETO REDUCTAE INHIBITORS AND THEIR USES |
AU2019362061A1 (en) | 2018-10-18 | 2021-05-06 | Essa Pharma, Inc. | Androgen receptor modulators and methods for their use |
CN109574917B (zh) * | 2018-12-03 | 2020-12-08 | 武汉尚赛光电科技有限公司 | 一种芴酮衍生物及其制备和应用 |
JP2022516057A (ja) | 2018-12-31 | 2022-02-24 | バイオメア フュージョン,エルエルシー | メニン-mll相互作用の不可逆的阻害剤 |
CA3125353A1 (en) | 2018-12-31 | 2020-07-09 | Biomea Fusion, Llc | Inhibitors of menin-mll interaction |
CN110981795B (zh) * | 2019-12-18 | 2021-02-12 | 武汉世纪久海检测技术有限公司 | 一种利用2-氰基异烟酸甲酯制备2-氨酰基异烟酸的方法 |
CA3174422A1 (en) | 2020-04-17 | 2021-10-21 | Essa Pharma, Inc. | Solid forms of an n-terminal domain androgen receptor inhibitor and uses thereof |
EP4387972A1 (en) | 2021-08-20 | 2024-06-26 | Biomea Fusion, Inc. | Crystalline form of n-[4-[4-(4-morpholinyl)-7h-pyrrolo[2,3-d]pyrimidin-6-yl]phenyl]-4-[[3(r)-[(1-oxo -2-propen-1-yl)amino]-1-piperidinyl]methyl]-2-pyridinecarboxamide, an irreversible menin-mll inhibitor for the treatment of cancer |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU6015796A (en) * | 1995-06-14 | 1997-01-15 | Yamanouchi Pharmaceutical Co., Ltd. | Fused imidazole derivatives and medicinal composition thereof |
MXPA03001422A (es) * | 2000-08-14 | 2004-01-26 | Johnson & Johnson | Pirazoles substituidos. |
WO2003055860A1 (en) * | 2001-12-21 | 2003-07-10 | Vernalis (Cambridge) Limited | 3,4-diarylpyrazoles and their use in the therapy of cancer |
GB0228417D0 (en) | 2002-12-05 | 2003-01-08 | Cancer Rec Tech Ltd | Pyrazole compounds |
GB0229618D0 (en) | 2002-12-19 | 2003-01-22 | Cancer Rec Tech Ltd | Pyrazole compounds |
CA2510298A1 (en) * | 2002-12-20 | 2004-07-15 | Pharmacia Corporation | Acyclic pyrazole compounds |
WO2004072081A1 (en) * | 2003-02-10 | 2004-08-26 | Cellular Genomics, Inc. | Certain 8-heteroaryl-6-phenyl-imidazo[1,2-a]pyrazines as modulators of kinase activity |
NZ541479A (en) | 2003-02-11 | 2008-11-28 | Vernalis Cambridge Liimited | Isoxazole compounds as inhibitors of heat shock proteins |
GB0309637D0 (en) | 2003-04-28 | 2003-06-04 | Cancer Rec Tech Ltd | Pyrazole compounds |
AU2004251949B2 (en) | 2003-06-27 | 2009-05-07 | Kyowa Hakko Kirin Co., Ltd. | Hsp90 family protein inhibitors |
GB0315111D0 (en) | 2003-06-27 | 2003-07-30 | Cancer Rec Tech Ltd | Substituted 5-membered ring compounds and their use |
EP1675861B1 (en) | 2003-08-29 | 2015-12-23 | Vernalis (R&D) Ltd. | Pyrimidothiophene compounds |
GB0323810D0 (en) * | 2003-10-10 | 2003-11-12 | Cancer Rec Tech Ltd | Pyridothiophene compounds |
US7538241B2 (en) * | 2003-12-26 | 2009-05-26 | Kyowa Hakko Kogyo Co., Ltd. | Hsp90 family protein inhibitors |
FR2884252B1 (fr) * | 2005-04-08 | 2007-05-18 | Aventis Pharma Sa | Nouveaux derives d'isoindoles, compositions les contenant, leur preparation et leurs utilisations pharmaceutiques notamment en tant qu'inhibiteurs d'activites de la proteine chaperone hsp90 |
-
2005
- 2005-05-19 FR FR0505037A patent/FR2885904B1/fr not_active Expired - Fee Related
-
2006
- 2006-05-12 DO DO2006000112A patent/DOP2006000112A/es unknown
- 2006-05-14 JO JO2006135A patent/JO2753B1/en active
- 2006-05-17 HN HN2006018410A patent/HN2006018410A/es unknown
- 2006-05-17 AR ARP060101980A patent/AR054125A1/es not_active Application Discontinuation
- 2006-05-17 PE PE2006000520A patent/PE20061367A1/es not_active Application Discontinuation
- 2006-05-18 PA PA20068675701A patent/PA8675701A1/es unknown
- 2006-05-18 GT GT200600206A patent/GT200600206A/es unknown
- 2006-05-18 MY MYPI20062304A patent/MY149037A/en unknown
- 2006-05-19 AT AT06755509T patent/ATE518859T1/de not_active IP Right Cessation
- 2006-05-19 NZ NZ563239A patent/NZ563239A/en not_active IP Right Cessation
- 2006-05-19 AU AU2006248825A patent/AU2006248825B2/en not_active Ceased
- 2006-05-19 CA CA2608378A patent/CA2608378C/fr not_active Expired - Fee Related
- 2006-05-19 KR KR1020077029644A patent/KR101288696B1/ko not_active IP Right Cessation
- 2006-05-19 UY UY29549A patent/UY29549A1/es unknown
- 2006-05-19 JP JP2008511754A patent/JP4964874B2/ja not_active Expired - Fee Related
- 2006-05-19 TW TW095117762A patent/TWI386406B/zh not_active IP Right Cessation
- 2006-05-19 CN CN2006800219737A patent/CN101203518B/zh not_active Expired - Fee Related
- 2006-05-19 MX MX2007014443A patent/MX2007014443A/es active IP Right Grant
- 2006-05-19 EP EP06755509A patent/EP1888579B1/fr active Active
- 2006-05-19 UA UAA200714230A patent/UA93203C2/ru unknown
- 2006-05-19 BR BRPI0611424-5A patent/BRPI0611424A2/pt not_active IP Right Cessation
- 2006-05-19 WO PCT/FR2006/001137 patent/WO2006123061A2/fr not_active Application Discontinuation
- 2006-05-19 EA EA200702531A patent/EA019027B1/ru unknown
-
2007
- 2007-10-18 TN TNP2007000389A patent/TNSN07389A1/en unknown
- 2007-11-05 IL IL187163A patent/IL187163A/en not_active IP Right Cessation
- 2007-11-13 CR CR9515A patent/CR9515A/es unknown
- 2007-11-14 US US11/939,735 patent/US7674795B2/en active Active
- 2007-11-15 ZA ZA2007/09856A patent/ZA200709856B/en unknown
- 2007-11-29 MA MA30431A patent/MA29493B1/fr unknown
- 2007-12-14 NO NO20076460A patent/NO20076460L/no not_active Application Discontinuation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DOP2006000112A (es) | Nuevos derivados de fluoreno, composiciones que los contienen y utilización | |
AR025698A1 (es) | Derivados de la quinolil propil piperidina, su preparacion y las composiciones farmaceuticas que los contienen. | |
BR0114994A (pt) | Composição de vacina | |
BRPI0514413A (pt) | forma cristalina de um composto de bifenil | |
ATE451910T1 (de) | Verwendung von benzotriazolderivaten zur photostabilisierung | |
ATE401877T1 (de) | Verwendung von methylenamid-derivaten bei kardiovaskulären erkrankungen | |
NO20060965L (no) | Inspeksjonskammer, sa vel som grunndeler derav | |
HRP20080330T3 (en) | Antitumoral compounds based on kahalalide f | |
NO20051282L (no) | Antitumorale analoger av lamellariner. | |
DE60202906D1 (de) | Solubilisierung von 1,3,5-Triazinderivaten mittels Estern von N-Acylaminosäuren | |
PT1185649E (pt) | Promotor do gene da miostatina e inibicao da sua activacao | |
DE60215256D1 (de) | Verwendung eines Ferulasäurederivats als Vorbeugungs- oder Heilmittel gegen Hypertonie | |
NO20035535L (no) | Gammasekretaseinhibitorer | |
BR0300119A (pt) | Composição aquosa, e, estrutura compósita | |
ID24846A (id) | Turunan-turunan bifenilamidina | |
MA30904B1 (fr) | Nouveaux derives du fluorene, compositions les contenant et utilisation comme inhibiteurs de la proteine chpaerone hsp90 | |
MXPA05009988A (es) | Derivados de 6-sulfonamida quinolina y cromeno como antagonistas de los receptores de androgenos. | |
ECSP045176A (es) | Derivados de 5-(piridin-3-il)-1-azabiciclo[3.2.1]octano, su preparacion y su aplicación en terapeutica | |
ATE348800T1 (de) | 4'-methansulfonylbiphenylderivate als hochselektive cyclooxygenase-2-inhibitoren | |
ATE350107T1 (de) | Verwendung von ungesättigten estern als duftstoffe | |
FR2878846B1 (fr) | Composes analogues de lipides membranaires d'archaebacteries et compositions liposomiales integrant de tel composes | |
HK1116188A1 (en) | Chromane and thiochromane-3-yl-1,3-dihydroimidazoles as inhibitors of dopamine-beta-hydroxylase and methods of their preparation | |
DE60323079D1 (de) | Umwandlung von taxanmolekülen | |
ATE407936T1 (de) | Aminomethyl substituiertes thiazolobenzimidazolderivat | |
DK1219599T3 (da) | Vitamin-D-derivater som har substituenter i 2-alfa-position |